Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study
- PMID: 7239110
Lactose enemas plus placebo tablets vs. neomycin tablets plus starch enemas in acute portal systemic encephalopathy. A double-blind randomized controlled study
Abstract
A randomized, double-blind comparison of lactose enemas plus placebo tablets vs. starch enemas plus neomycin tablets was performed on 18 patients with acute portal systemic encephalopathy. Ten patients received starch enemas (10%; 1000 ml t.i.d.) plus neomycin tablets and 8 patients received lactose enemas (20%; 1000 ml t.i.d.) plus placebo tablets. A significant mental state improvement was demonstrated in the group of patients treated with starch enemas-neomycin tablets (p less than 0.05) and in the group of patients treated with lactose enemas-placebo tablets (p less than 0.025). Both treatments significantly improved the frequency of asterixis, ammonia blood levels, and electroencephalograms. In addition, patients treated with lactose enemas showed significant improvement in number-connection test times (p less than 0.02), and their stools showed a more acid pH (p less than 0.05). No side effects were evident with either treatment. Lactose enemas are a safe and effective treatment for acute portal systemic encephalopathy.
Similar articles
-
Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.Gastroenterology. 1977 Apr;72(4 Pt 1):573-83. Gastroenterology. 1977. PMID: 14049 Clinical Trial.
-
Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial.Hepatology. 1987 Jul-Aug;7(4):639-43. doi: 10.1002/hep.1840070404. Hepatology. 1987. PMID: 3301614 Clinical Trial.
-
Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy.Am J Gastroenterol. 1983 Aug;78(8):517-22. Am J Gastroenterol. 1983. PMID: 6881119 Clinical Trial.
-
Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.Hepatology. 1997 Jun;25(6):1351-60. doi: 10.1002/hep.510250609. Hepatology. 1997. PMID: 9185752 Clinical Trial.
-
Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy.Hepatogastroenterology. 1992 Dec;39(6):542-5. Hepatogastroenterology. 1992. PMID: 1483668 Clinical Trial.
Cited by
-
Treatment of chronic portal--systemic encephalopathy with vegetable and animal protein diets. A controlled crossover study.Dig Dis Sci. 1982 Dec;27(12):1109-16. doi: 10.1007/BF01391449. Dig Dis Sci. 1982. PMID: 6756833 Clinical Trial.
-
Flapping Tremor: Unraveling Asterixis-A Narrative Review.Medicina (Kaunas). 2024 Feb 21;60(3):362. doi: 10.3390/medicina60030362. Medicina (Kaunas). 2024. PMID: 38541088 Free PMC article. Review.
-
Progress in the treatment of chronic portasystemic encephalopathy.Gut. 1984 Jan;25(1):85-98. doi: 10.1136/gut.25.1.85. Gut. 1984. PMID: 6360816 Free PMC article. Review. No abstract available.
-
Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial.Dig Dis Sci. 1987 Dec;32(12):1345-53. doi: 10.1007/BF01296659. Dig Dis Sci. 1987. PMID: 3319453 Clinical Trial.
-
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.Clin Mol Hepatol. 2020 Apr;26(2):83-127. doi: 10.3350/cmh.2019.0010n. Epub 2020 Jan 10. Clin Mol Hepatol. 2020. PMID: 31918536 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources